Search Results

IceCure Medical Ltd. today reported financial results as of and for the three months ended March 31, 2024.

IceCure Medical Ltd. today announced the Company’s management, will participate in the Northland Capital Markets Virtual Growth Conference on Tuesday, June 25, 2024.

IceCure Medical Ltd. today reported sales as of and for the twelve months ended December 31, 2023.

IceCure Medical Ltd. (NASDAQ: ICCM) (“IceCure”, “IceCure Medical” or the “Company”) today announced it has received marketing authorization from the United States Food and Drug Administration (the “FDA”) for its next-generation single probe cryoablation system, the XSense™ Cryoablation System with CryoProbes.

IceCure Medical Ltd. announced today that it will issue a press release containing its financial and operational results as of and for the three months ended March 31, 2024 before the Nasdaq Stock Market opens on Tuesday, May 28, 2024.

IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”) today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2023 before the Nasdaq Stock Market opens on Wednesday, April 3, 2024.

IceCure Medical Ltd. announced today that it will issue a press release containing its financial and operational results as of and for the three months ended March 31, 2024 before the Nasdaq Stock Market opens on Tuesday, May 28, 2024.

IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”) today announced that data from an interim analysis of its ICESECRET kidney cancer trial were presented at the 3rd Annual Israeli Conference on Interventional Radiology in Tel Aviv, Israel on June 10, 2024.

IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”) today announced the U.S. Food and Drug Administration (“FDA”) will convene a Medical Device Advisory Committee for a panel meeting (the “Advisory Panel”) to obtain independent expert advice on scientific, technical, and policy matters related to ProSense® to help the FDA make a sound decision.